Furthermore, it would argue that approaches to inhibit YAP/TAZ could promote YAPon-to-YAPoff cancer conversion in certain circumstances, such as combining YAP/TEAD inhibitors with EGFR inhibitors in NSCLC, which has been suggested as a potential therapeutic strategy [151]. The gene discussed is YAP1; the disease is cancer.